Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.

Author: AroraSujata, ChasenMartin R, GridelliCesare, ModianoManuel R, NavariRudolph M, PomaAllen, RapoportBernardo L, SchnadigIan D, SchwartzbergLee S, UrbanLaszlo

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the efficacy of rolapitant in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Paper Details　
Original Abstract of the Article :
Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days after treatment. We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone, for the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(15)00034-0

データ提供：米国国立医学図書館（NLM）

Chemotherapy-Induced Nausea and Vomiting: A Storm in the Gut

Chemotherapy, a powerful weapon in the fight against cancer, can sometimes trigger a tempestuous storm in the gut, causing nausea and vomiting. This debilitating side effect can significantly impact patient quality of life and compliance with treatment. This research explores the effectiveness of rolapitant, a neurokinin-1 receptor antagonist, in preventing chemotherapy-induced nausea and vomiting.

A Randomized Trial in the Stormy Sea

The study, a randomized, active-controlled, double-blind, phase 3 trial, evaluated the efficacy of rolapitant in combination with other anti-nausea medications in patients receiving moderately emetogenic chemotherapy. The results demonstrated that rolapitant significantly reduced the incidence and severity of nausea and vomiting, suggesting its potential as a valuable tool for managing this challenging side effect of chemotherapy.

Calming the Storm

This research offers a beacon of hope in the turbulent sea of chemotherapy-induced nausea and vomiting. Rolapitant's ability to suppress this debilitating side effect could significantly improve patient well-being and treatment compliance, allowing patients to navigate the challenges of cancer treatment with greater comfort and resilience.

Dr. Camel's Conclusion

This research is like a calm oasis in the midst of a stormy sea, providing a refuge from the debilitating side effects of chemotherapy. Rolapitant's ability to quell nausea and vomiting could significantly improve the quality of life for cancer patients, allowing them to focus on their recovery and healing. Just as a traveler in the desert seeks shelter from the harsh sun, cancer patients can find respite in the protective embrace of rolapitant.
Date :
  1. Date Completed 2015-12-14
  2. Date Revised 2022-11-09
Further Info :

Pubmed ID

26272768

DOI: Digital Object Identifier

10.1016/S1470-2045(15)00034-0

Related Literature

Article Analysis
・Side Effects of rolapitant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.